Breast cancer

Group leader: Isabel Álvarez, M.D.

Donostialdea IHO

Strategic Objectives

  • To contribute to the development of programmes which optimise a personalised approach to the treatment of breast cancer patients, taking into account the specific characteristics of both the tumour and the cancer patient.
  • Clinical research: To continue and promote the creation of clinical trials to develop new diagnostic and therapeutic strategies, and more specifically studies into new drugs.
  • Developing new programmes for translational research, either as independent studies or as studies in parallel to or associated with clinical trials. The goal is to develop and implement new molecular techniques that may be diagnostically and predictively relevant to the optimisation of treatments suitable to each molecular subtype.
  • Development of studies in the areas of epidemiology and the follow-up of breast cancer patients.

Main lines of research

  • Study of the presence and prognostic significance of status heterogeneity in the receptors between the primary tumour and the synchronous lymph node metastasis in hormone receptor-positive breast cancers.
  • Circulating tumoural stem cells in breast cancer.
  • Comparison between the clinical-pathological features of interval breast cancers (IC) and those detected in the programmed screening among the participants in the Basque Health Service’s breast cancer detection programme.
  • Use of next-generation sequencing technology to analyse genetic differences between the primary tumour and metastatic sites.
  • Identification and validation of circulating miRNA/RNA as non-invasive markers for breast cancer.
  • Use of shRNA/miRNA coding viral libraries in order to identify factors of resistance to drugs and new therapies in breast cancer.

Team Members

Name Surname Center E-mail
Nerea Ancizar Lizarraga Donostialdea IHO
María Cristina Churruca Galaz Donostialdea IHO
María Díez Zubizarreta Donostialdea IHO
Marta Fernández Calleja Donostialdea IHO
Elena Guimón Olaizola Donostialdea IHO
Ana Paisán Ruiz Donostialdea IHO
Marta Rezola Bajineta Donostialdea IHO
Jose María Urraca De La Serna Donostialdea IHO
Ander Urruticoechea Ribate Onkologikoa Fundazioa


Scientific Output


Published: 10 / 17

Early stage ovarian cancer clinical behavior according to FIGO 2014 Staging changes with a focus on IC subtype: data from prospective GEICO registry.

Romero I, Churruca CM, Redondo A, Santaballa A, Calvo E, Ojeda B, Del Campo JM, Lainez N, Garcia-Martinez E, Romeo M, Bover I, Mendiola C, Caballero C, Martinez J, Herrero A, Sanchez AB, De Juan A, Hernando S, Lopez-Guerrero JA, Poveda A, GEICO.

J. Clin. Oncol. 2015; 33. FI: 18.428 (Q1).

Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study.

Martin M, Ruiz A, Ruiz Borrego M, Barnadas A, Gonzalez S, Calvo L, Margeli Vila M, Anton A, Rodriguez-Lescure A, Segui-Palmer MA, Munoz-Mateu M, Dorca Ribugent J, Lopez-Vega JM, Jara C, Espinosa E, Mendiola Fernandez C, Andres R, Ribelles N, Plazaola A, Sanchez-Rovira P, Salvador Bofill J, Crespo C, Carabantes FJ, Servitja S, Chacon JI, Rodriguez CA, Hernando B, Alvarez I, Carrasco E, Lluch A.

J. Clin. Oncol. 2013; 31: 2593-2599. FI: 18.038 (Q1).

Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.

Cufi S, Corominas-Faja B, Lopez-Bonet E, Bonavia R, Pernas S, Alvarez Lopez I, Dorca J, Martinez S, Batista Lopez N, Dominguez Fernandez S, Cuyas E, Visa J, Rodriguez-Gallego E, Quirantes-Pine R, Segura-Carretero A, Joven J, Martin-Castillo B, Menendez JA, Metten 10 Investigators.

Oncotarget. 2013; 4: 1484-1495. FI: 6.636 (Q1).

New imaging and molecular biomarkers to predict pathological response to bevacizumab-based treatment in neoadjuvant breast cancer.

García-Foncillas J, Plazaola A, Hernando B, Sánchez R, Álvarez I, Anton A, Martínez Del Prado P, Llombart A, Sherer S, López-vega jm.

Ann. oncol. 2012; 23: 82-83. FI: 6.425 (Q1).

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer Final Results from the Spanish Breast Cancer Group 2001-03 Phase 2 Randomized Trial.

Llombart-Cussac A, Ruiz A, Anton A, Barnadas A, Antolin S, Ales-Martínez JE, Álvarez I, Andres R, García Saenz JA, Lao J, Carrasco E, Cámara C, Casas I, Martín M.

Cancer. 2012; 118: 241-247. FI: 4.771 (Q1).

Survey of the Perceived Quality of Patient Care in a Radiation Oncology Service: Results From 2002-2011.

Eguiguren Bastida M, Minguez J, Blanco C, Urraca J, Querejeta A, Uranga I, Ciria J, Rodríguez G, Caffiero S, Guimon E. A.

Int. J. Radiat. Oncol. Biol. Phys. 2012; 84: 541-0. FI: 4.105 (Q1).

Treatment innovations for metastatic breast cancer: Nanopartiele albumin-bound (NAB) technology targeted to tumors.

Lluch A, Alvarez I, Munoz M, Angel Segui M, Tusquets I, Garcia-Estevez L.

CRIT REV ONCOL HEMAT. 2014; 89: 62-72. FI: 4.046 (Q1).

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers.

Bastien RRL, Rodríguez-Lescure A, Ebbert MTW, Prat A, Munarriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Álvarez I, Dowell T, Wall D, Segui MA, Barley, Lee B, Kenneth M, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Anton A, Carrasco E, Caballero R, Ellis MJ, Nielsen TO, Perou CM, Astill M, Bernard PS, Martín M.

BMC Med. Genomics. 2012; 5: -0. FI: 3.693 (Q2).

The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy.

Gamez-Pozo A, Perez Carrion RM, Manso L, Crespo C, Mendiola C, Lopez-Vacas R, Berges-Soria J, Alvarez Lopez I, Margeli M, Bayo Calero JL, Gonzalez X, Santaballa A, Ciruelos EM, Afonso R, Lao J, Catalan G, Alvarez JV, Miramon J, Salvador FJ, Ruiz M, Espinosa E, Vara JA, Fresno P.

PLoS One. 2014; 9: e109611. FI: 3.534 (Q1).

Immunohistochemical expression of GATA 3 in vulvar Paget disease.

Gomez MDC, Ruiz I, Rezola M, Caballero MC, Silva MJ.

Virchows Arch. 2014; 465: 356-0. FI: 2.560 (Q2).


Published: 1 / 1

Finding the right dose of fulvestrant in breast cancer.

Estevez L, Alvarez I, Tusquets I, Segui MA, Munoz M, Fernandez Y, Lluch A.

Cancer Treat. Rev. 2013; 39: 136-141. FI: 6.024 (Q1).


Published: 0 / 0


Published: 0 / 0


Published: 0 / 0


Projects 2 / 2

Heterogeneidad en la expresión de marcadores biológicos entre el tumor primario y la metástasis ganglionar axilar sincrónica en cáncer de mama con receptores hormonales positivos.

Investigador principal: Isabel Álvarez López. Entidad financiadora: Gobierno Vasco, Departamento de Salud. Año inicio: 2012. Año final: 2015.

Estudio de la heterogeneidad en la expresión de marcadores biológicos entre el tumor primario y la metástasis ganglionar axilar sincrónica en cáncer de mama con receptores hormonales positivos.

Investigador Principal: Isabel Álvarez López. Entidad Financiadora: Departamento de Industria. Año inicio: 2012. Año final: 2013.